Dr. Edward R. Arrowsmith, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,521
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Vanderbilt University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license MD27014 · GA license 049528
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Erlanger Medical Center Chattanooga, TN
- Parkridge Medical Center Chattanooga, TN
- Commonspirit-Memorial Hospital-North Georgia Ringgold, GA
Medical groups
- Tennessee Oncology PLLC (358 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,521
- Services billed
- 125,365
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 45,000 | 37 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22,200 | 20 |
| Injection, pembrolizumab, 1 mg | 18,800 | 20 |
| Blood test, comprehensive group of blood chemicals | 3,576 | 1,016 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,250 | 27 |
| Injection, denosumab, 1 mg | 2,940 | 16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,630 | 365 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,346 | 42 |
| Insertion of needle into vein for collection of blood sample | 1,332 | 321 |
| Ferritin (blood protein) level | 1,183 | 495 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 407 |
| Prednisone Other prescribers in Chattanooga, TN | 378 |
| Letrozole Other prescribers in Chattanooga, TN | 51 |
| Acyclovir Other prescribers in Chattanooga, TN | 40 |
| Imbruvica (ibrutinib) | 40 |
| Anastrozole Other prescribers in Chattanooga, TN | 39 |
| Ondansetron Odt (ondansetron) Other prescribers in Chattanooga, TN | 39 |
| Imatinib Mesylate | 36 |
| Dexamethasone Other prescribers in Chattanooga, TN | 35 |
| Xtandi (enzalutamide) | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 37 payments worth $1,092 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $138 |
|---|---|
| Kite Pharma, Inc. | $111 |
| Novartis Pharmaceuticals Corporation | $106 |
| Daiichi Sankyo Inc. | $85.73 |
| Aveo Pharmaceuticals, Inc. | $81.19 |
| E.r. Squibb & Sons, L.l.c. | $75.51 |
| Celgene Corporation | $71.02 |
| Regeneron Healthcare Solutions, Inc. | $70.58 |
| Food and Beverage | $1,092 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $98,353 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma
Merck Sharp & Dohme LLC - A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
Epizyme, Inc. · Terminated · NCT04179864 - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203 - A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company · Active, not recruiting · NCT05288166 - A phase 3 randomized doubleblind placebocontrolled study of talazoparib with enzalutamide in metastatic castrationresistant prostate cancer
Pfizer Inc. - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensiti…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.